After a trendsetting role in global biotech venture investing, David Mott parts ways with NEA
About 12 years ago, David Mott jumped from the CEO suite at MedImmune — after AstraZeneca bought it for $15.6 billion — into one of the busiest roles in biotech venture investing at New Enterprise Associates.
Now he’s hitting the exit, which a spokesperson for NEA says is due to “personal reasons” with plans to spend the bulk of his time wth his family. Mohamad Makhzoumi has been named global head of healthcare investing to replace him in that top spot at NEA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.